Dexcom Announces $1 Billion Share Repurchase Program Through 2027
Dexcom, Inc. (DXCM) has announced that its Board of Directors has authorized a new share repurchase program totaling up to $1 billion. The program allows the company to buy back its outstanding common stock over the next several years. The authorization is set to remain in effect until no later than December 31, 2027. This move signals management's confidence in the company's long-term value and provides a mechanism for returning capital to shareholders.
Tickers: $DXCM
Topics: board authorization capital allocation share repurchase program